Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens

View More View Less
  • 1 Division of Neurosurgery, Department of Neurology, Department of Pathology, and the Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles, California
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object. An approach toward the treatment of intracranial gliomas was developed in a rat experimental model. The authors investigated the ability of “professional” antigen-presenting cells (dendritic cells) to enhance host antitumor immune responses when injected as a vaccine into tumor-bearing animals.

Methods. Dendritic cells, the most potent antigen-presenting cells in the body, were isolated from rat bone marrow precursors stimulated in vitro with granulocyte—macrophage colony-stimulating factor (GM-CSF) and interleukin-4. Cultured cell populations were confirmed to be functional antigen-presenting cells on the basis of expressed major histocompatibility molecules, as analyzed by fluorescence-activated cell sorter cytofluorography. These dendritic cells were then pulsed (cocultured) ex vivo with acid-eluted tumor antigens from 9L glioma cells. Thirty-eight adult female Fischer 344 rats harboring 7-day-old intracranial 9L tumors were treated with three weekly subcutaneous injections of either control media (10 animals), unpulsed dendritic cells (six animals), dendritic cells pulsed with peptides extracted from normal rat astrocytes (10 animals), or 9L tumor antigen—pulsed dendritic cells (12 animals). The animals were followed for survival. At necropsy, the rat brains were removed and examined histologically, and spleens were harvested for cell-mediated cytotoxicity assays.

The results indicate that tumor peptide-pulsed dendritic cell therapy led to prolonged survival in rats with established intracranial 9L tumors implanted 7 days prior to the initiation of vaccine therapy in vivo. Immunohistochemical analyses were used to document a significantly increased perilesional and intratumoral infiltration of CD8+ and CD4+ T cells in the groups treated with tumor antigen—pulsed dendritic cells compared with the control groups. In addition, the results of in vitro cytotoxicity assays suggest that vaccination with these peptide-pulsed dendritic cells can induce specific cytotoxic T lymphocytes against 9L tumor cells.

Conclusions. Based on these results, dendritic antigen-presenting cells pulsed with acid-eluted peptides derived from autologous tumors represent a promising approach to the immunotherapy of established intracranial gliomas, which may serve as a basis for designing clinical trials in patients with brain tumors.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Address reprint requests to: Linda M. Liau, M.D., Division of Neurosurgery, University of California at Los Angeles School of Medicine, NPI 18-228, 10833 Le Conte Avenue, Los Angeles, California 90095. email: liau@ucla.edu.
  • 1.

    Armstrong CA, , Botella R, & Galloway TH, et al: Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56:21912198, 1996 Armstrong CA, Botella R, Galloway TH, et al: Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56:2191–2198, 1996

    • Search Google Scholar
    • Export Citation
  • 2.

    Ashley DM, , Faiola B, & Nair S, et al: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:11771182, 1997 Ashley DM, Faiola B, Nair S, et al: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177–1182, 1997

    • Search Google Scholar
    • Export Citation
  • 3.

    Bakker ABH, , Marland G, & de Boer AJ, et al: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55:53305334, 1995 Bakker ABH, Marland G, de Boer AJ, et al: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55:5330–5334, 1995

    • Search Google Scholar
    • Export Citation
  • 4.

    Bañuls MP, , Alvarez A, & Ferrero I, et al: Cell-surface marker analysis of rat thymic dendritic cells. Immunology 79:298304, 1993 Bañuls MP, Alvarez A, Ferrero I, et al: Cell-surface marker analysis of rat thymic dendritic cells. Immunology 79:298–304, 1993

    • Search Google Scholar
    • Export Citation
  • 5.

    Boczkowski D, , Nair SK, & Snyder D, et al: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465472, 1996 Boczkowski D, Nair SK, Snyder D, et al: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472, 1996

    • Search Google Scholar
    • Export Citation
  • 6.

    Bouma GJ, , van der Meer-Prins PM, & van Bree FP, et al: Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol 5:8592, 1992 Bouma GJ, van der Meer-Prins PM, van Bree FP, et al: Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol 5:85–92, 1992

    • Search Google Scholar
    • Export Citation
  • 7.

    Brenan M, & Puklavec M: The MRC OX62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of an integrin. J Exp Med 175:14571465, 1992 Brenan M, Puklavec M: The MRC OX62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of an integrin. J Exp Med 175:1457–1465, 1992

    • Search Google Scholar
    • Export Citation
  • 8.

    Caux C, , Dezutter-Dambuyant C, & Schmitt D, et al: GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258261, 1992 Caux C, Dezutter-Dambuyant C, Schmitt D, et al: GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258–261, 1992

    • Search Google Scholar
    • Export Citation
  • 9.

    Chen-Woan M, , Delaney CP, & Fournier V, et al: In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol 59:196207, 1996 Chen-Woan M, Delaney CP, Fournier V, et al: In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol 59:196–207, 1996

    • Search Google Scholar
    • Export Citation
  • 10.

    Chen-Woan M, , Delaney CP, & Fournier V, et al: A new protocol for the propagation of dendritic cells from rat bone marrow using recombinant GM-CSF, and their quantification using the mAb OX-62. J Immunol Methods 178:157171, 1995 Chen-Woan M, Delaney CP, Fournier V, et al: A new protocol for the propagation of dendritic cells from rat bone marrow using recombinant GM-CSF, and their quantification using the mAb OX-62. J Immunol Methods 178:157–171, 1995

    • Search Google Scholar
    • Export Citation
  • 11.

    Constant S, , Sant'Angelo D, & Pasqualini T, et al: Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. J Immunol 154:49154923, 1995 Constant S, Sant'Angelo D, Pasqualini T, et al: Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. J Immunol 154:4915–4923, 1995

    • Search Google Scholar
    • Export Citation
  • 12.

    Couraud PO: Interactions between lymphocytes, macrophages, and central nervous system cells. J Leuko Biol 56:407415, 1994 Couraud PO: Interactions between lymphocytes, macrophages, and central nervous system cells. J Leuko Biol 56:407–415, 1994

    • Search Google Scholar
    • Export Citation
  • 13.

    Davis FG, , Freels S, & Grutsch J, et al: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:110, 1998 Davis FG, Freels S, Grutsch J, et al: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, epidemiology, and end results (SEER) data, 1973–1991. J Neurosurg 88:1–10, 1998

    • Search Google Scholar
    • Export Citation
  • 14.

    Dranoff G, , Jaffee E, & Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:35393543, 1993 Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543, 1993

    • Search Google Scholar
    • Export Citation
  • 15.

    Fakhrai H, , Dorigo O, & Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93:29092914, 1996 Fakhrai H, Dorigo O, Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 93:2909–2914, 1996

    • Search Google Scholar
    • Export Citation
  • 16.

    Hsu FJ, , Benike C, & Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:5258, 1996 Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58, 1996

    • Search Google Scholar
    • Export Citation
  • 17.

    Inaba K, , Inaba M, & Romani N, et al: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:16931702, 1992 Inaba K, Inaba M, Romani N, et al: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693–1702, 1992

    • Search Google Scholar
    • Export Citation
  • 18.

    Kurpad SN, , Wikstrand CJ, & Bigner DD: Immunobiology of malignant astrocytomas. Semin Oncol 21:149161, 1994 Kurpad SN, Wikstrand CJ, Bigner DD: Immunobiology of malignant astrocytomas. Semin Oncol 21:149–161, 1994

    • Search Google Scholar
    • Export Citation
  • 19.

    Leach DR, , Krummel MF, & Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:17341736, 1996 Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736, 1996

    • Search Google Scholar
    • Export Citation
  • 20.

    Levin D, , Constant S, & Pasqualini T, et al: Role of dendritic cells in the priming of CD4+ lymphocytes to peptide antigen in vivo. J Immunol 151:67426748, 1993 Levin D, Constant S, Pasqualini T, et al: Role of dendritic cells in the priming of CD4+ lymphocytes to peptide antigen in vivo. J Immunol 151:6742–6748, 1993

    • Search Google Scholar
    • Export Citation
  • 21.

    Lichtor T, , Glick RP, & Kim TS, et al: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:10381044, 1995 Lichtor T, Glick RP, Kim TS, et al: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:1038–1044, 1995

    • Search Google Scholar
    • Export Citation
  • 22.

    Mayordomo JI, , Zorina T, & Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:12971302, 1995 Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297–1302, 1995

    • Search Google Scholar
    • Export Citation
  • 23.

    Okada H, , Tahara H, & Shurin MR, et al: Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196201, 1998 Okada H, Tahara H, Shurin MR, et al: Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196–201, 1998

    • Search Google Scholar
    • Export Citation
  • 24.

    Paglia P, , Chiodoni C, & Rodolfo M, et al: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317322, 1996 Paglia P, Chiodoni C, Rodolfo M, et al: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317–322, 1996

    • Search Google Scholar
    • Export Citation
  • 25.

    Porgador A, , Snyder D, & Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:29182926, 1996 Porgador A, Snyder D, Gilboa E: Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 156:2918–2926, 1996

    • Search Google Scholar
    • Export Citation
  • 26.

    Rapoport SL: Blood-Brain Barrier in Physiology and Medicine. New York: Raven Press, 1976 Rapoport SL: Blood-Brain Barrier in Physiology and Medicine. New York: Raven Press, 1976

    • Search Google Scholar
    • Export Citation
  • 27.

    Reid CDL, , Stackpoole A, & Meager A, et al: Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 149:26812688, 1992 Reid CDL, Stackpoole A, Meager A, et al: Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 149:2681–2688, 1992

    • Search Google Scholar
    • Export Citation
  • 28.

    Rubin JT, & Lotze MT: Adoptive cellular immunotherapy of cancer, in Mitchell MS (ed): Biological Approaches to Cancer Treatment: Biomodulation. New York: McGraw-Hill, 1993, pp 379410 Rubin JT, Lotze MT: Adoptive cellular immunotherapy of cancer, in Mitchell MS (ed): Biological Approaches to Cancer Treatment: Biomodulation. New York: McGraw-Hill, 1993, pp 379–410

    • Search Google Scholar
    • Export Citation
  • 29.

    Sallusto F, & Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:11091118, 1994 Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109–1118, 1994

    • Search Google Scholar
    • Export Citation
  • 30.

    Sampson JH, , Archer GE, & Ashley DM, et al: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 93:1039910404, 1996 Sampson JH, Archer GE, Ashley DM, et al: Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the “immunologically privileged” central nervous system. Proc Natl Acad Sci USA 93:10399–10404, 1996

    • Search Google Scholar
    • Export Citation
  • 31.

    Schneider J, , Hofman FM, & Apuzzo MLJ, et al: Cytokines and immunoregulatory molecules in malignant glial neoplasms. J Neurosurg 77:265273, 1992 Schneider J, Hofman FM, Apuzzo MLJ, et al: Cytokines and immunoregulatory molecules in malignant glial neoplasms. J Neurosurg 77:265–273, 1992

    • Search Google Scholar
    • Export Citation
  • 32.

    Schuler G, & Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:11831187, 1997 Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186:1183–1187, 1997

    • Search Google Scholar
    • Export Citation
  • 33.

    Song W, , Kong HL, & Carpenter H, et al: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186:12471256, 1997 Song W, Kong HL, Carpenter H, et al: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186:1247–1256, 1997

    • Search Google Scholar
    • Export Citation
  • 34.

    Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271296, 1991 Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296, 1991

    • Search Google Scholar
    • Export Citation
  • 35.

    Storkus WJ, , Zeh HJ III, & Salter RD, et al: Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 14:94103, 1993 Storkus WJ, Zeh HJ III, Salter RD, et al: Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J Immunother 14:94–103, 1993

    • Search Google Scholar
    • Export Citation
  • 36.

    Sudo Y, , Shimazaki C, & Ashihara E, et al: Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 89:31863191, 1997 Sudo Y, Shimazaki C, Ashihara E, et al: Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 89:3186–3191, 1997

    • Search Google Scholar
    • Export Citation
  • 37.

    Szabolcs P, , Moore MAS, & Young JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 154:58515861, 1995 Szabolcs P, Moore MAS, Young JW: Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J Immunol 154:5851–5861, 1995

    • Search Google Scholar
    • Export Citation
  • 38.

    Volgmann T, , Klein-Struckmeier A, & Mohr H: A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J Immunol Methods 119:4551, 1989 Volgmann T, Klein-Struckmeier A, Mohr H: A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J Immunol Methods 119:45–51, 1989

    • Search Google Scholar
    • Export Citation
  • 39.

    Young JW, & Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:711, 1996 Young JW, Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7–11, 1996

    • Search Google Scholar
    • Export Citation
  • 40.

    Zitvogel L, , Mayordomo JI, & Tjandrawan T, et al: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:8797, 1996 Zitvogel L, Mayordomo JI, Tjandrawan T, et al: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87–97, 1996

    • Search Google Scholar
    • Export Citation
  • 41.

    Zorina T, , Mayordomo J, & Watkins S, et al: Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J Immunother 16:247, 1994 (Abstract) Zorina T, Mayordomo J, Watkins S, et al: Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNF-alpha. J Immunother 16:247, 1994 (Abstract)

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 581 366 48
Full Text Views 305 22 4
PDF Downloads 144 11 3
EPUB Downloads 0 0 0